high density of beef cattle production (1.2 million head) with approximately 51% (600K) housed in confined 24 feeding operations at a given time within the region (Alberta-Government 2014). We observed that selection 25 for resistance to ciprofloxacin in C. jejuni in beef cattle in confined feeding operations was subtype-dependent 26 (Webb et al. 2018) . Furthermore, the characteristics of C. jejuni in beef cattle coupled with the observation that 27 C. jejuni subtypes infecting people are also commonly associated with beef cattle suggests that cattle are an 28 important zoonotic reservoir contributing to the high rates of campylobacteriosis in SWA. Enrofloxacin (i.e. 29 Baytril®) is a broad-spectrum antibiotic registered in Canada and USA for therapeutic use against bacterial 30 bovine respiratory disease (BRD). In their decision, the Veterinary Drug Directorate of Health Canada (HC) 31 indicated that "the result of our Health Risk Assessment shows that residues at the above noted concentrations 32 will not pose any undue health risk for consumers". However, HC has stated that "should there be an apparent 33 risk of increasing resistance to this drug as a result of usage in beef cattle, Health Canada will ensure that 34 appropriate interventions will be taken which could, if necessary, lead to withdrawal of the product from the 35 market" (http://www.hc-sc.gc.ca/dhp-mps/vet/faq/baytril_qa-qr-eng.php). Notably, resistance rates to 36 ciprofloxacin in C. jejuni from diarrheic humans started to increase in SWA in 2004, the year that enrofloxacin 37 was registered for use in cattle (our unpublished data). 38 Limited research has examined fluoroquinolone resistance in C. jejuni of beef cattle. Englen (Englen et al. 39 2005) observed that only 1.8% of C. jejuni isolates from US feedlot cattle (1999) (2000) were resistant to 40 ciprofloxacin. Furthermore, Rao et al. (Rao et al. 2010 ) observed low resistance to ciprofloxacin (2.6%) in C. 41 jejuni from beef cattle in Alberta in 2004. We similarly observed that resistance rates to ciprofloxacin in C. 42 jejuni were low (<0.3%) in beef cattle housed in an experimental feedlot; however, these cattle were not 43 administered fluoroquinolone antibiotics at any point during the feedlot period (Inglis et al. 2005) . In contrast, 44 Tang et al. (Tang et al. 2017 ) observed that resistance rates to ciprofloxacin in C. jejuni from feedlot cattle in 45 the USA in 2012-2013 were 35.6%, which was substantially higher than reported previously by Englen et al. 46 (Englen et al. 2005) . However, Smith et al. (Smith et al. 2017 ) administered Baytril® to beef cattle, and 47 D r a f t Inglis, Zaytsoff, Selinger, Taboada, Uwiera Canadian Journal of Microbiology Page 4 observed no measureable difference in resistance rates to C. jejuni; however, the number of isolates examined 48 were small thereby limiting the conclusions regarding selection of resistance. We observed in a large-scale 49 study of commercial feedlots in SWA that ciprofloxacin resistance was approximately 2.2 times more prevalent 50 in C. jejuni isolates recovered from beef cattle exiting feedlots relative to isolates recovered from animals 51 entering the feedlots; although a correlation with enrofloxacin administration to cattle was not detected 52 (unpublished) . Given the increasing rates of fluoroquinolone resistance observed in people, coupled with the 53 increasing rates of resistance to ciprofloxacin observed in C. jejuni associated with beef cattle in the USA and 54 Canada, and a growing recognition of cattle as a reservoir of infectious subtypes of the bacterium (de Haan et 55 al. 2010; Webb et al. 2018) indicates that issue fluoroquinolone resistance in C. jejuni associated with cattle 56 warrants further examination.
57
Bayril® is approved for subcutaneous administration to cattle for up to 5 days to treat BRD (Plumb 2011 
Inoculation of mice with Campylobacter jejuni

95
Campylobacter jejuni NCTC 11168 passed through a human was used (Lone et al. 2013; Thomas et al. 2014); 96 this strain was determined to be highly sensitive to ciprofloxacin before commencement of the study (i.e. Administration of enrofloxacin or saline commenced 4 days post-inoculation (p.i.) with C. jejuni (Fig. 1) .
114
Therapeutic doses of enrofloxacin were administered every 24 hr (q24h) (Plumb 2011 Campylobacter jejuni in feces and digesta was quantified by PCR as described previously (Lone et al. 2013 was detected in feces ( Fig. 2A-C jejunum, ileum, cecum, and colon) within 6 hr of administration, and excreted in feces by 8 hr.
231
Campylobacter jejuni densities in feces and digesta
232
No C. jejuni DNA was detected in feces from mice not inoculated with the bacterium (Fig. 3A) . In contrast, C.
233
jejuni DNA was detected in the feces of all inoculated mice inoculated over the 12 day duration of the study 234 ( Fig. 3A-D) . Furthermore, DNA of C. jejuni was only detected in digesta from the cecum and colon of all D r a f t Inglis, Zaytsoff, Selinger, Taboada, Uwiera Canadian Journal of Microbiology Page 10 contrast, administration of enrofloxacin equally decreased (P≤0.040) densities of C. jejuni in cecal digesta 238 regardless of treatment, and in colonic digesta (P≤0.034) only for treatments E4, E5, and EP (Fig. 4) .
239
Total bacterial and Enterobacteriaceae densities in feces and digesta
240
The administration of enrofloxacin subcutaneously and per os did not affect (P≥0.215) densities of total 241 bacteria, Firmicutes, or Bacteroidetes in cecal digesta as determined by qPCR (Fig. 5A-C) . Enterobacteriaceae 242 contributed a relatively small number of bacterial cells to the bacterial community in cecal digesta.
243
Enrofloxacin administered subcutaneously reduced (P=0.004) densities for the E1 and E2 treatments, but did 244 not completely eliminate of Enterobacteriaceae within cecal digesta (Fig. 5D ). We have observed increasing resistance to ciprofloxacin in C. jejuni isolates from diarrheic humans in SWA 
263
We hypothesized that enrofloxacin administered subcutaneously in mice will be manifested as biocidal 264 activity in feces equal to the bioactivity of the antibiotic administered per os. We observed that bioactivity 265 within murine feces was equivalent regardless of the route of administration, consistent with our hypothesis. suggesting that the bacterium was exposed to selection pressure within the intestine; the cecum is a primary 299 location of C. jejuni colonization in mice (Lone et al. 2013 ) (Delsol et al. 2004) . The shift in the MIC that we observed is far below the breakpoint value denoting 328 ciprofloxacin resistance in C. jejuni (i.e. 8 µg ml involved in ciprofloxacin resistance (Drlica and Zhao 1997; Iovine 2013 ). In the current study we used a single 331 model strain of C. jejuni known to undergo spontaneous mutation and selection for fluoroquinolone resistance.
D r a f t Inglis, Zaytsoff, Selinger, Taboada, Uwiera Canadian Journal of Microbiology Page 13 However, some evidence indicates that selection for fluoroquinolone resistance may be subtype specific 333 including C. jejuni isolated from cattle (Cha et al. 2017 ). colonization and to examine pathogenesis by C. jejuni (Bereswill et al. 2011; Iizumi et al. 2016; O'Loughlin et al. 343 2015). In the current study, enrofloxacin administration did not enhance colonization success by C. jejuni NCTC 344 11168 (i.e. relative to the non-antibiotic control treatment), although our study examined colonization success 345 before and simultaneously with administration of enrofloxacin, and not ciprofloxacin.
346
We hypothesized that enrofloxacin administered subcutaneously would affect densities of commensal Enterobacteriaceae (Gismondo et al. 1995; Perrin-Guyomard et al. 2005 digesta and feces may be bound to organic materials (Ahn et al. 2011; Griffith et al. 2010) , and the biological 355 relevance of bound ciprofloxacin, including as a function of metabolic conversion from enrofloxacin to 356 ciprofloxacin, to commensal enteric bacteria is currently uncertain.
357
In conclusion, we observed that enrofloxacin administered for short duration to mice subcutaneously (CG; treatments C1, E1,  E2 , E3, E4, E5, and EP) or buffer alone (SG; treatment C2). On day 5 mice were administered enrofloxacin (ES) or saline (SS) by subcutaneous injection (treatments C1, C2, E1, E2, E3, E4, and E5), or enrofloxacin per os by gavage (EP). Feces was collected from all mice commencing on day 5 (T0), and daily thereafter for 7 days (T1 to T7). Mice were humanely euthanized on day 12, and intestinal samples were collected during necropsy (N). D r a f t Fig. 1 . Experimental design. The experiment consisted of eight treatments with three replicates conducted on separate occasions. Mice were gavage inoculated on Day 1 with Campylobacter jejuni (CG; treatments C1, E1, E2, E3, E4, E5, and EP) or buffer alone (SG; treatment C2). On day 5 mice were administered enrofloxacin (ES) or saline (SS) by subcutaneous injection (treatments C1, C2, E1, E2, E3, E4, and E5), or enrofloxacin per os by gavage (EP). Feces was collected from all mice commencing on day 5 (T0), and daily thereafter for 7 days (T1 to T7). Mice were humanely euthanized on day 12, and intestinal samples were collected during necropsy (N).
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